These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20424485)

  • 1. Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
    Kamal F; Yanakieva-Georgieva N; Piao H; Morioka T; Oite T
    Nephron Exp Nephrol; 2010; 115(3):e69-79. PubMed ID: 20424485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis.
    Mahmood J; Khan F; Okada S; Kumagai N; Morioka T; Oite T
    Kidney Int; 2006 Nov; 70(9):1591-8. PubMed ID: 16985512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
    Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
    Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
    J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
    Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
    Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
    Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
    Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
    Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli.
    Xu ZG; Yoo TH; Ryu DR; Cheon Park H; Ha SK; Han DS; Adler SG; Natarajan R; Kang SW
    Kidney Int; 2005 Mar; 67(3):944-52. PubMed ID: 15698433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
    Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE
    Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
    Motawi TK; El-Maraghy SA; Senousy MA
    J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
    Vieitez P; Gómez O; Uceda ER; Vera ME; Molina-Holgado E
    J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
    Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
    J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy.
    Lee FT; Cao Z; Long DM; Panagiotopoulos S; Jerums G; Cooper ME; Forbes JM
    J Am Soc Nephrol; 2004 Aug; 15(8):2139-51. PubMed ID: 15284299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockade attenuates glomerulosclerosis progression by promoting VEGF expression and bone marrow-derived cells recruitment.
    Song SM; Wang CC; Qi SH; Xing L; Yang BF; Oite T; Li B
    Nephrol Dial Transplant; 2012 Jul; 27(7):2712-9. PubMed ID: 22140134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
    Hofni A; El-Moselhy MA; Taye A; Khalifa MM
    Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
    Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.
    Satoh M; Fujimoto S; Arakawa S; Yada T; Namikoshi T; Haruna Y; Horike H; Sasaki T; Kashihara N
    Nephrol Dial Transplant; 2008 Dec; 23(12):3806-13. PubMed ID: 18596126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
    Kato S; Luyckx VA; Ots M; Lee KW; Ziai F; Troy JL; Brenner BM; MacKenzie HS
    Kidney Int; 1999 Sep; 56(3):1037-48. PubMed ID: 10469372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.